Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-09-16 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Evusheld positive CHMP opinion in EU
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated 16 September 2022, indicating it is a regulatory announcement disseminated via the RNS service of the London Stock Exchange. The content is a press release detailing a positive opinion from the European Medicines Agency's CHMP regarding AstraZeneca's drug Evusheld for COVID-19 treatment. This type of material—a specific, time-sensitive announcement of regulatory or clinical news that doesn't fit the definition of a full financial report (10-K, IR, ER, MDA)—is best classified as a general Regulatory Filing (RNS), which serves as the primary category for miscellaneous regulatory news releases on this platform. It is not a Report Publication Announcement (RPA) because it is the substantive news itself, not merely an announcement that a report is available.
2022-09-16 English
Nirsevimab recommended for approval in EU by CHMP
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated September 16, 2022, originating from AstraZeneca PLC and distributed via RNS (Regulatory News Service), indicated by the 'RNS Number : 7319Z' header. The content details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorisation recommendation for the drug Beyfortus in the EU. This is a specific, time-sensitive update about regulatory progress and clinical trial results, not a comprehensive annual report (10-K), a full interim report (IR), or a general earnings release (ER). Since it is a formal regulatory announcement distributed through a service like RNS, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly branded as an RNS release.
2022-09-16 English
FORXIGA APPROVED IN CHINA FOR CKD
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the approval of Forxiga in China for chronic kidney disease, including clinical trial results and company statements. The document is not an annual or interim financial report, nor is it a transcript, audit report, or management change announcement. It is a regulatory filing providing material information about the company's product approval and related clinical data. The length of the document (11,875 characters) and the detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-06 English
IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the FDA approval of Imfinzi for biliary tract cancer, including clinical trial results, regulatory status, and company information. The document is not a full financial report, audit report, or earnings release. It is a regulatory filing providing material information about a product approval and related clinical data. The document length is about 14,140 characters, which is consistent with a detailed regulatory announcement rather than a brief report publication announcement. There is no indication that this is a transcript, management report, or capital update. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-06 English
Forxiga approved in China for CKD
Regulatory Filings Classification · 100% confidence The document is identified by the header 'RNS Number' and contains a date (05 September 2022) and a brief announcement regarding a regulatory approval (Forxiga approved in China). The text is structured as a news release detailing a specific event (drug approval) rather than a comprehensive financial report (like 10-K or IR) or a transcript. The presence of the RNS distribution boilerplate at the end strongly suggests this is a general regulatory announcement disseminated via the London Stock Exchange's news service. Since it is a specific, non-financial regulatory update (drug approval), it fits best under the general 'Regulatory Filings' category (RNS), as it is not covered by the more specific categories like ER, AR, or LTR, and it is not an announcement *about* a report (RPA).
2022-09-05 English
Imfinzi approved in US for biliary tract cancer
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 1907Y' and is dated '05 September 2022'. It announces a specific regulatory event: the US FDA approval of Imfinzi plus chemotherapy for advanced biliary tract cancer, citing Phase III trial results. The presence of the RNS header, the specific date/time stamp, and the nature of the announcement (a significant corporate/regulatory event) strongly indicate this is a regulatory news service release. Since it is an announcement of a regulatory/clinical development milestone rather than a full financial report (like 10-K or IR) or a general press release, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official market communications distributed via the London Stock Exchange's news service.
2022-09-05 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.